It has long been observed that heart failure (HF) is associated with measures of systemic
inflammation. In recent years, there have been significant advancements in our …

Galectin-3 is a member of the galectin family, which are β‑galactoside‑binding lectins with≥
1 evolutionary conserved carbohydrate‑recognition domain. It binds proteins in a …

In response to injury, hemodynamic changes, or neurohormonal activation, the heart
undergoes a series of structural and functional changes that have been termed cardiac …

Heart failure is a global public health problem that affects more than 26 million people
worldwide. The global burden of heart failure is growing and is expected to increase …

Since natriuretic peptides were successfully integrated into the clinical practice of heart
failure (HF), the possibility of using new biomarkers to advance the management of affected …

The aim of this narrative review is to summarize contemporary evidence on the use of
circulating cardiac biomarkers of heart failure (HF) and to identify a promising biomarker …

Background The prevalence of cardiovascular disease (CVD) has been continuously
increasing, and this trend is projected to continue. CVD is rapidly becoming a significant …

In patients with heart failure, the beneficial effects of drug and device therapies counteract to
some extent ongoing cardiac damage. According to the net balance between these two …

The use of circulating biomarkers for heart failure (HF) is engrained in contemporary
cardiovascular practice and provides objective information about various pathophysiological …

Cardiovascular disease (CVD) and cancer are leading causes of morbidity and mortality
worldwide. Although conventionally managed as separate disease processes, recent …